avoralstat

Phase 1Small molecule

BBioCryst Pharmaceuticals

avoralstat is one of 23 small molecule programs targeting Diabetic Macular Edema. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic Macular EdemaRecruiting

Diabetic Macular EdemaPhase 1

Recruiting

Competition

Competitive Landscape

32 competitors in Diabetic Macular Edema

#DrugCompanyPhaseTrials

Eylea

Regeneron

Approved

54 2

Vabysmo

Roche

Approved

12 3

Beovu

Novartis

Approved

6 4

Decadron

AAspen Global Incorporated

Approved

13 5

Amaryl

Sanofi

Approved

1 6

Aldactone

Pfizer

Approved

1 7

Kenalog

BBassett Healthcare

Approved

4 8

Klor-Con

Jardiance

1 10

Intravitreal Ranibizumab

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hereditary Angioedema1 trial

Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema

Terminated·BBioCryst Pharmaceuticals·Phase 3·NCT02670720·6 enrolled

Diabetic Macular Edema1 trial

A Study of Avoralstat In Participants With Diabetic Macular Edema

Recruiting·BBioCryst Pharmaceuticals·Phase 1·NCT07228559·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for avoralstat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — avoralstat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for avoralstat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioCryst Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBioCryst Pharmaceuticals

avoralstat

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hereditary Angioedema1 trial

Diabetic Macular Edema1 trial

References

Drug Info

Quick Facts

Related News